<DOC>
	<DOCNO>NCT00705640</DOCNO>
	<brief_summary>RATIONALE : Vaccine therapy may help body build effective immune response kill tumor cell . PURPOSE : This randomized clinical trial study well vaccine therapy work treat patient advanced melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Advanced Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - To assess circulate CD8 T-cell response vaccination multipeptide vaccine patient advance melanoma . - To determine whether immunization peptide incomplete Freund 's adjuvant induces lymph-node-like aggregate ( LNLA ) tertiary lymphoid organ ( TLOs ) skin patient . - To determine whether extended immunization ( vaccination 4-6 ) associate induction negative immune-regulatory process vaccination site microenvironment/TLO . - To characterize peptide-reactive CD4 CD8 T cell loco site immunization multipeptide vaccine . - To characterize expression toll-like receptor 4 , 7 , 8 , 9 , MyD88 dendritic cell infiltrate vaccination site course 6 vaccination vaccination . OUTLINE : Patients randomize 1 10 arm . All patient receive primary vaccine comprise melanoma multipeptides tetanus toxoid helper peptide emulsify incomplete Freund 's adjuvant , half volume subcutaneously ( SC ) half intradermally ( ID ) , 6 time 7 week day 1 , 8 , 15 , 29 , 36 , 43 . Vaccines administer single skin location extremity clinically uninvolved melanoma . A replicate vaccine site identify patient skin biopsy replica vaccine administration . - Arm 1A : Patients receive replicate vaccine . Patients undergo surgical biopsy replicate vaccine site day 1 . - Arm 1B : Patients receive replicate vaccine comprise incomplete Freund 's adjuvant SC ID day 1 undergo surgical biopsy replicate vaccine site day 8 ( 1 week replicate vaccine 1 ) . - Arm 1C : Patients receive replicate vaccine comprise incomplete Freund 's adjuvant SC ID day 1 , 8 , 15 undergo surgical biopsy replicate vaccine site day 22 ( 1 week replicate vaccine 3 ) . - Arm 1D : Patients receive replicate vaccine comprise incomplete Freund 's adjuvant SC ID day 1 , 8 , 15 , 29 , 36 , 43 undergo surgical biopsy replicate vaccine site day 50 ( 1 week replicate vaccine 6 ) . Patients evaluate 1-3 week biopsy . - Arm 1E : Patients receive replicate vaccine comprise incomplete Freund 's adjuvant SC ID day 1 , 8 , 15 , 29 , 36 , 43 undergo surgical biopsy replicate vaccine site day 85 ( 6 week replicate vaccine 6 ) . Patients evaluate 1-3 week biopsy . - Arm 2A : Patients receive replicate vaccine . Patients undergo surgical biopsy replicate vaccine site day 1 . - Arm 2B : Patients receive replicate vaccine ( primary vaccine ) SC ID day 1 undergo surgical biopsy replicate vaccine site day 8 ( 1 week replicate vaccine 1 ) . - Arm 2C : Patients receive replicate vaccine ( primary vaccine ) SC ID day 1 , 8 , 15 undergo surgical biopsy replicate vaccine site day 22 ( 1 week replicate vaccine 3 ) . - Arm 2D : Patients receive replicate vaccine ( primary vaccine ) SC ID day 1 , 8 , 15 , 29 , 36 , 43 undergo surgical biopsy replicate vaccine site day 50 ( 1 week replicate vaccine 6 ) . Patients evaluate 1-3 week biopsy . - Arm 2E : Patients receive replicate vaccine ( primary vaccine ) SC ID day 1 , 8 , 15 , 29 , 36 , 43 undergo surgical biopsy replicate vaccine site day 85 ( 1 week replicate vaccine 6 ) . Patients evaluate 1-3 week biopsy . Tissue biopsy examine reverse transcriptase-PCR , IHC , protein analysis , flow cytometry , western blot . Blood sample collect periodically examine ELIspot assay , tetramer staining , proliferation assay . After completion study therapy , patient follow annually .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Conjunctival Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm melanoma meet one follow criterion : Stage IIBIV melanoma render clinically free disease surgery , therapy , spontaneous remission within past 6 month Stage III IV melanoma disease Persistent metastatic disease allow RECIST criterion measurable disease meet Multiple primary melanoma allow Prior concurrent metastasis cutaneous , mucosal , ocular , unknown primary site allow No clinically detectable melanoma deem likely investigator require intervention first 12 week study would require premature discontinuation ( e.g. , untreated bone metastasis risk fracture rapidly progressive lowvolume disease ) Brain metastasis allow follow criterion meet : The total number brain metastasis ever ≤ 3 The brain metastases completely remove surgery treat completely stereotactic radiotherapy There evident growth brain metastasis since treatment No treat brain metastasis &gt; 2 cm diameter At least two intact axillary and/or inguinal lymph node basins Prior lymph node biopsy allow lymphoscintigraphy demonstrates intact drainage node basin If sentinal lymph node locate lymphoscintigraphy , patient eligible study HLAA1 , A2 , A3 , A11 positive Either eligible , refuse interferon therapy OR candidate interferon therapy follow reason : Active ischemic heart disease cerebrovascular disease Anginal syndrome require ongoing medication history myocardial infarction arrhythmia disorder History treatment depression , active depression , psychiatric disorder Autoimmune disorder Hypersensitivity interferonalfa component associate interferon therapy Debilitating medical condition severe pulmonary disease severe diabetes mellitus Thyroid abnormality , thyroid function maintain normal range without medication Resected stage IV melanoma Discontinued interferon therapy due occurrence major toxicity document treat physician Experienced tumor progression interferon complete interferon therapy Missed standardofcare enrollment window interferon therapy initiation PATIENT CHARACTERISTICS : ECOG performance status 01 ANC &gt; 1,000/mm^3 Platelets &gt; 100,000/mm^3 Hemoglobin &gt; 9 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN Hepatitis C HIV negative ( antibody screen ) Hemoglobin_A1C level &lt; 7 % Body weight ≥ 110 pound Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study treatment No New York Heart Association class IIIIV heart disease No known suspect allergy component vaccine No medical contraindication potential problem complying requirement protocol PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior peptide vaccine ( include MELITAC 12.1 similar vaccine ) nonpeptide vaccine allow At least 1 week since prior stereotactic radiotherapy , gamma knife No influenza vaccine ≥ 2 week , , ≥ 2 week completion study therapy More 4 week since prior concurrent use follow : Systemic cytotoxic chemotherapy ( 6 week nitrosoureas ) Radiotherapy Other experimental therapy Agents putative immunomodulating activity ( exception nonsteroidal antiinflammatory agent topical steroid ) Allergy desensitization injection Systemic corticosteroid , administer parenterally orally Inhaled steroid ( e.g. , fluticasone propionate [ Advair® Flovent® ] triamcinolone acetonide [ Azmacort® ] ) Topical corticosteroid steroids low solubility administer nasally local effect allow ( e.g. , mometasone furoate [ Nasonex® ] ) Growth factor ( e.g. , sargramostim [ GMCSF ] , filgrastim [ GCSF ] , epoetin alfa ) Interferon therapy Aldesleukin interleukins Street drug At least 1 month since prior concurrent investigational drug therapy At least 12 week since prior melanoma vaccine patient recur progressed either treatment vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>conjunctival melanoma</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
</DOC>